May 24, 2017

Nordic Nanovector ASA – Results for First Quarter 2017

Continued progress in clinical development programmes with Betalutin®  Oslo, Norway, 24 May 2017 Nordic Nanovector ASA (OSE: NANO) announces results for the first quarter...
Read more
May 23, 2017

Onxeo Announces 10th Positive DSMB Recommendation to Continue Livatag® ReLive Phase III Trial in HCC

Paris (France), May 23, 2017 - 6.00 pm CEST - Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), a clinical-stage biotechnology company specializing in the development o...
Read more
May 23, 2017

Aprea Therapeutics Announces First Patients Enrolled in Phase Ib/II Clinical Study of APR-246 for the Treatment of Myelodysplastic Syndrome

BOSTON and STOCKHOLM, May 23, 2017 /PRNewswire/ Aprea Therapeutics, a privately held, clinical stage biopharmaceutical company developing novel anticancer therapies targeting the t...
Read more
May 23, 2017

New Data from Two Multi-Center Randomized Clinical Trials Demonstrate That Zephyr Endobronchial Valves Deliver Benefit to Both Heterogeneous and Homogenous Emphysema Patients without Collateral Ventilation

WASHINGTON & REDWOOD CITY, Calif.--(BUSINESS WIRE)-- Pulmonx®, Inc. today announced the results of two multi-center, randomized clinical trials showing clinically meaningful i...
Read more
May 22, 2017

Wilson Therapeutics Strengthens its Board of Directors by the Appointments of Birgitte Volck and Björn Odlander

The Annual General Meeting of Wilson Therapeutics AB (publ), has elected Dr. Birgitte Volck and Dr. Björn Odlander as new members of the Board of Directors. Dr. Birgitte Volck ...
Read more
May 22, 2017

BONESUPPORT™ Announces First Patient Enrolled in FORTIFY Trial with CERAMENT®|G, a novel injectable, antibiotic-eluting bone graft substitute

Lund, Sweden, 22 May 2017– BONESUPPORT AB, an emerging leader in innovative injectable bioceramic bone substitute products to treat bone voids caused by trauma, infection, diseas...
Read more
May 19, 2017

Safety Review Committee Approves the Continued Evaluation of the 20 MBq/kg Betalutin® with 100 mg/m2 Lilotomab Regimen in Phase 2 Cohort in NHL

Oslo, Norway, 19 May 2017 Nordic Nanovector ASA (OSE: NANO) announces that the Safety Review Committee (SRC) for the ongoing LYMRIT 37-01 clinical trial of Betalutin® in non-Ho...
Read more
May 19, 2017

Nexstim Plc Updates the Timeline for its Supplementary E-FIT Phase III Trial in Stroke Rehabilitation

Company announcement, Helsinki, 19 May 2017 at 9:00 am   Nexstim Plc (NXTMH:HEX, NXTMS:STO) ("Nexstim" or "Company"), a  medical  technology company developing and mar...
Read more
May 19, 2017

Wilson Therapeutics to present at Bioequity Europe

May 19, 2017 Jonas Hansson, Chief Executive Officer, will present Wilson Therapeutics at the 18thannual Bioequity Europe investor conference that will be held May 22-23,...
Read more
May 18, 2017

Targovax ASA: ASCO abstract released

Oslo, Norway, 18 May 2017: Targovax ASA ("Targovax" or "the Company"; OSE: TRVX), a clinical stage company focused on developing immuno-oncology therapies to target treatment-resis...
Read more